Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Bevacizumab/Erlotinib Adds Another Option to Frontline EGFR+ NSCLC

Jason M. Broderick @jasoncology
Published: Wednesday, Apr 10, 2019

Lung cancer Findings from the phase III NEJ026 study, presented at the 2018 ASCO Annual Meeting and now published in Lancet Oncology,1 showed that adding bevacizumab (Avastin) to erlotinib (Tarceva) significantly improved progression-free survival (PFS) versus erlotinib alone in patients with EGFR-positive, advanced nonsquamous non–small cell lung cancer (NSCLC).

-positive NSCLC.

In the phase III FLAURA study, the third-generation EGFR TKI osimertinib (Tagrisso) reduced the risk of progression or death by 54% versus standard therapy with either erlotinib or gefitinib.2 The median PFS was 18.9 months (95% CI, 15.2-21.4) with osimertinib compared with 10.2 months (95% CI, 9.6-11.1) for standard treatment (HR, 0.46; 95% CI, 0.37-0.57; P <.0001).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication